vs

Side-by-side financial comparison of MarketAxess (MKTX) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

MarketAxess is the larger business by last-quarter revenue ($233.4M vs $151.7M, roughly 1.5× Tarsus Pharmaceuticals, Inc.). MarketAxess runs the higher net margin — 33.4% vs -5.5%, a 38.9% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs 11.9%). MarketAxess produced more free cash flow last quarter ($15.9M vs $13.0M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 8.7%).

MarketAxess Holdings Inc. is an international financial technology company that operates an electronic trading platform for the institutional credit markets, and also provides market data and post-trade services. It enables institutional investors and broker-dealers to trade credit instruments, including corporate bonds, and other types of fixed income products.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

MKTX vs TARS — Head-to-Head

Bigger by revenue
MKTX
MKTX
1.5× larger
MKTX
$233.4M
$151.7M
TARS
Growing faster (revenue YoY)
TARS
TARS
+116.5% gap
TARS
128.4%
11.9%
MKTX
Higher net margin
MKTX
MKTX
38.9% more per $
MKTX
33.4%
-5.5%
TARS
More free cash flow
MKTX
MKTX
$2.9M more FCF
MKTX
$15.9M
$13.0M
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
8.7%
MKTX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
MKTX
MKTX
TARS
TARS
Revenue
$233.4M
$151.7M
Net Profit
$78.0M
$-8.4M
Gross Margin
Operating Margin
43.2%
-5.3%
Net Margin
33.4%
-5.5%
Revenue YoY
11.9%
128.4%
Net Profit YoY
418.5%
63.8%
EPS (diluted)
$2.20
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MKTX
MKTX
TARS
TARS
Q1 26
$233.4M
Q4 25
$209.4M
$151.7M
Q3 25
$208.8M
$118.7M
Q2 25
$219.5M
$102.7M
Q1 25
$208.6M
$78.3M
Q4 24
$202.4M
$66.4M
Q3 24
$206.7M
$48.1M
Q2 24
$197.7M
$40.8M
Net Profit
MKTX
MKTX
TARS
TARS
Q1 26
$78.0M
Q4 25
$92.2M
$-8.4M
Q3 25
$68.2M
$-12.6M
Q2 25
$71.1M
$-20.3M
Q1 25
$15.1M
$-25.1M
Q4 24
$65.1M
$-23.1M
Q3 24
$71.5M
$-23.4M
Q2 24
$64.9M
$-33.3M
Operating Margin
MKTX
MKTX
TARS
TARS
Q1 26
43.2%
Q4 25
36.3%
-5.3%
Q3 25
41.0%
-12.2%
Q2 25
41.9%
-21.6%
Q1 25
42.4%
-33.5%
Q4 24
39.5%
-36.8%
Q3 24
42.1%
-52.3%
Q2 24
41.2%
-81.6%
Net Margin
MKTX
MKTX
TARS
TARS
Q1 26
33.4%
Q4 25
44.0%
-5.5%
Q3 25
32.6%
-10.6%
Q2 25
32.4%
-19.8%
Q1 25
7.2%
-32.1%
Q4 24
32.2%
-34.8%
Q3 24
34.6%
-48.7%
Q2 24
32.9%
-81.6%
EPS (diluted)
MKTX
MKTX
TARS
TARS
Q1 26
$2.20
Q4 25
$2.49
$-0.17
Q3 25
$1.84
$-0.30
Q2 25
$1.91
$-0.48
Q1 25
$0.40
$-0.64
Q4 24
$1.74
$-0.57
Q3 24
$1.90
$-0.61
Q2 24
$1.72
$-0.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MKTX
MKTX
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$377.3M
$417.3M
Total DebtLower is stronger
$72.4M
Stockholders' EquityBook value
$1.2B
$343.4M
Total Assets
$2.3B
$562.2M
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MKTX
MKTX
TARS
TARS
Q1 26
$377.3M
Q4 25
$519.7M
$417.3M
Q3 25
$473.3M
$401.8M
Q2 25
$462.8M
$381.1M
Q1 25
$486.2M
$407.9M
Q4 24
$544.5M
$291.4M
Q3 24
$446.3M
$317.0M
Q2 24
$434.1M
$323.6M
Total Debt
MKTX
MKTX
TARS
TARS
Q1 26
Q4 25
$72.4M
Q3 25
$72.3M
Q2 25
$72.1M
Q1 25
$72.0M
Q4 24
$71.8M
Q3 24
$71.7M
Q2 24
$71.6M
Stockholders' Equity
MKTX
MKTX
TARS
TARS
Q1 26
$1.2B
Q4 25
$1.1B
$343.4M
Q3 25
$1.4B
$335.1M
Q2 25
$1.4B
$332.6M
Q1 25
$1.3B
$342.5M
Q4 24
$1.4B
$224.5M
Q3 24
$1.4B
$237.5M
Q2 24
$1.3B
$252.2M
Total Assets
MKTX
MKTX
TARS
TARS
Q1 26
$2.3B
Q4 25
$1.9B
$562.2M
Q3 25
$2.0B
$534.6M
Q2 25
$2.0B
$495.0M
Q1 25
$1.9B
$500.8M
Q4 24
$1.8B
$377.0M
Q3 24
$1.8B
$376.3M
Q2 24
$1.9B
$376.8M
Debt / Equity
MKTX
MKTX
TARS
TARS
Q1 26
Q4 25
0.21×
Q3 25
0.22×
Q2 25
0.22×
Q1 25
0.21×
Q4 24
0.32×
Q3 24
0.30×
Q2 24
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MKTX
MKTX
TARS
TARS
Operating Cash FlowLast quarter
$19.3M
Free Cash FlowOCF − Capex
$15.9M
$13.0M
FCF MarginFCF / Revenue
6.8%
8.6%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$581.0M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MKTX
MKTX
TARS
TARS
Q1 26
Q4 25
$382.1M
$19.3M
Q3 25
$90.2M
$18.3M
Q2 25
$103.7M
$-29.4M
Q1 25
$29.6M
$-20.7M
Q4 24
$385.2M
$-22.2M
Q3 24
$95.1M
$-8.7M
Q2 24
$118.8M
$-14.4M
Free Cash Flow
MKTX
MKTX
TARS
TARS
Q1 26
$15.9M
Q4 25
$373.9M
$13.0M
Q3 25
$88.7M
$16.3M
Q2 25
$102.5M
$-30.4M
Q1 25
$27.7M
$-21.2M
Q4 24
$375.3M
$-22.3M
Q3 24
$94.3M
$-8.9M
Q2 24
$111.2M
$-15.4M
FCF Margin
MKTX
MKTX
TARS
TARS
Q1 26
6.8%
Q4 25
178.6%
8.6%
Q3 25
42.5%
13.8%
Q2 25
46.7%
-29.6%
Q1 25
13.3%
-27.1%
Q4 24
185.4%
-33.5%
Q3 24
45.6%
-18.6%
Q2 24
56.2%
-37.8%
Capex Intensity
MKTX
MKTX
TARS
TARS
Q1 26
Q4 25
3.9%
4.2%
Q3 25
0.7%
1.6%
Q2 25
0.5%
1.0%
Q1 25
0.9%
0.8%
Q4 24
4.9%
0.1%
Q3 24
0.4%
0.6%
Q2 24
3.9%
2.5%
Cash Conversion
MKTX
MKTX
TARS
TARS
Q1 26
Q4 25
4.14×
Q3 25
1.32×
Q2 25
1.46×
Q1 25
1.97×
Q4 24
5.91×
Q3 24
1.33×
Q2 24
1.83×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MKTX
MKTX

Commissions$203.5M87%
Information services$14.4M6%
Post-trade services$11.6M5%
Technology services$3.9M2%

TARS
TARS

Segment breakdown not available.

Related Comparisons